Sanofi (SNY)

盈利方式

Sanofi earns revenue when wholesalers, hospitals and health systems buy its medicines and vaccines, at prices that vary widely by country depending on each government's negotiation power and reimbursement rules. Newer biologic drugs under patent, above all Dupixent, carry high prices and wide margins; once a patent expires, cheaper generic or biosimilar copies typically enter and revenue from that product falls quickly. Vaccines are a full year of sales in 2025 of about €7.9 billion, roughly a fifth of group sales.

Patents on biologic drugs like Dupixent grant years of exclusive pricing before copies can enter, and building the clinical evidence and regulatory approvals behind a new medicine is slow and expensive for challengers to replicate. The moat is narrow rather than wide because each patent has a known expiration date after which the protection disappears product by product.

People need treatment for chronic and acute illness regardless of the state of the economy, so underlying demand for medicines and vaccines is stable. The variable that moves results year to year is less the economic cycle and more the pace of patent expirations, new drug launches and pricing negotiations with governments.

主要风险

• Patent expiration and biosimilar competition — Loss of patent protection typically brings a rapid, significant drop in revenue for the affected product as lower-priced copies enter; Dupixent, the largest single product, faces this risk later this decade.
• Government pricing pressure — Drug-pricing reform in the United States and cost-containment policies in Europe can force lower prices or restrict reimbursement, directly reducing what Sanofi collects per unit sold.
• Research and development failure — Replacing revenue lost to patent expirations depends on a pipeline of experimental drugs that mostly fail in clinical trials or regulatory review, so future growth is not guaranteed.
• Product liability and litigation — As with any pharmaceutical maker, claims alleging harm from a marketed drug can lead to costly litigation and settlements, and to reputational damage that affects prescribing habits.